Search
Paltusotine
go.drugbank.com/drugs/DB16277ApprovedInvestigationalhormone (GH) and decreases the production of growth-promoting insulin-like growth factor 1 (IGF-1). … Paltusotine is a selective somatostatin receptor agonist: It mimics the biological actions of endogenous somatostatin, which activates the somatostatin 2 receptor (SST2) to block the secretion of growth
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsCipepofol
go.drugbank.com/drugs/DB16295ApprovedInvestigationalCipepofol is an intravenous general anesthetic of the alkylphenol class, supplied as a sterile lipid emulsion, which is thought to act by positively modulating the inhibitory function of GABA at ligand-gated … GABA-A receptors, similar to the previously approved [propofol].
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalRezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. … Rezafungin is an echinocandin antifungal drug.
Categories: Heterocyclic Compounds, 1-RingSynonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalSepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. … It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Categories: Heterocyclic Compounds, 2-RingSynonyms: L-sepiapterinMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). … It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsFosdenopterin
go.drugbank.com/drugs/DB16628Approved(cPMP) - is interrupted. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.
Categories: MATE 1 Substrates, MATE 2 InhibitorsSynonyms: C(PMP)KW-2450 free base
go.drugbank.com/drugs/DB16637InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingReltecimod
go.drugbank.com/drugs/DB16687InvestigationalReltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Categories: Antigens, Differentiation, T-Lymphocyte, Costimulatory and Inhibitory T-Cell ReceptorsSynonyms: D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-aspartyl-D-alanineNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. … Nirmatrelvir (PF-07321332) is an orally bioavailable 3C-like protease (3CL<sup>PRO</sup>) inhibitor that is the subject of clinical trial NCT04756531.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDurlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigationalDurlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases. … [A263306] It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of _Acinetobacter baumannii-calcoaceticus_
Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTER